Keywords: fragmin, fails, achieve, primary, endpoint, frisc, ii
Fragmin fails to achieve primary endpoint in FRISC II, but supports
Article | 11 March 1999
Prolonged treatment with Pharmacia & Upjohn's low molecular weightheparin product Fragmin (dalteparin sodium) leads to a reduction in death and nonfatal ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
